Spectrum Pharmaceuticals, Inc. was added to the Russell 2000®, Russell 3000®, and the Russell Global® indexes on July 1, 2009. We are also a member of the Nasdaq Biotechnology Index.
Spectrum Pharmaceuticals, Inc.'s ticker symbol is SPPI and is traded on the Nasdaq Global Market System.
Spectrum Pharmaceuticals, Inc. can be found under the CUSIP number 847 63A 10 8.
Spectrum's transfer agent is Computershare and can be contacted at:
Questions regarding stock certificates and other pertinent information should be relayed to our transfer agent or a registered broker.
Investor inquiries regarding Spectrum Pharmaceuticals, Inc. should be directed to:
For financial information, please contact Investor Relations at:
The Annual Meeting of Stockholders typically takes place in the middle of each year. Further information regarding the date will be available on our website once the date has been set.
Our auditors are Deloitte & Touche LLP ("D&T")
Spectrum currently has three drug candidates that are no longer under active development; SPI-339, SPI-376 and SPI-392. Spectrum still retains the intellectual property rights to these products, and intends to out-license these compounds if possible. Currently, there are no plans to resurrect these products into active development.
For a list of links to current clinical trials click here.
Please submit your question using the form below. * Required fields
10:27 AM ET on Mar 30, 2017
Delayed at least 20 minutes.
Provided by eSignal.